US5993434A
(en)
*
|
1993-04-01 |
1999-11-30 |
Genetronics, Inc. |
Method of treatment using electroporation mediated delivery of drugs and genes
|
US5702359A
(en)
*
|
1995-06-06 |
1997-12-30 |
Genetronics, Inc. |
Needle electrodes for mediated delivery of drugs and genes
|
US6261281B1
(en)
|
1997-04-03 |
2001-07-17 |
Electrofect As |
Method for genetic immunization and introduction of molecules into skeletal muscle and immune cells
|
WO1999001158A1
(fr)
*
|
1997-06-30 |
1999-01-14 |
Rhone-Poulenc Rorer S.A. |
Amelioration du transfert d'acide nucleique dans le muscle strie et combinaison permettant la mise en oeuvre du procede
|
CZ299638B6
(cs)
*
|
1997-06-30 |
2008-10-01 |
Rhone-Poulenc Rorer S. A. |
Lécivo pro genovou terapii, které se vnáší do nádoru za aplikace slabého elektrického pole, a kombinovaný produkt pro genovou terapii
|
US6241701B1
(en)
|
1997-08-01 |
2001-06-05 |
Genetronics, Inc. |
Apparatus for electroporation mediated delivery of drugs and genes
|
US6055453A
(en)
|
1997-08-01 |
2000-04-25 |
Genetronics, Inc. |
Apparatus for addressing needle array electrodes for electroporation therapy
|
US20040229363A1
(en)
*
|
1998-06-24 |
2004-11-18 |
Ed Nolan |
High efficiency transfection based on low electric field strength, long pulse length
|
EP2428250A1
(fr)
|
1998-07-13 |
2012-03-14 |
Genetronics, Inc. |
Thérapie génique ciblant la peau et les muscles par champ magnétique pulsé
|
US7922709B2
(en)
|
1998-07-13 |
2011-04-12 |
Genetronics, Inc. |
Enhanced delivery of naked DNA to skin by non-invasive in vivo electroporation
|
US6678556B1
(en)
|
1998-07-13 |
2004-01-13 |
Genetronics, Inc. |
Electrical field therapy with reduced histopathological change in muscle
|
EP1148885A4
(fr)
*
|
1999-02-08 |
2002-05-08 |
Chiron Corp |
Augmentation electriquement induite de l'immunite et de l'efficacite de vaccins d'adn in vivo
|
US6593130B1
(en)
|
1999-04-16 |
2003-07-15 |
The Regents Of The University Of California |
Method and apparatus for ex vivo and in vivo cellular electroporation of gene protein or drug therapy
|
BR0108959A
(pt)
*
|
2000-03-03 |
2003-10-14 |
Valentis Inc |
Composições de poloxmero ou poloxamina melhoradas para distribuição de ácido nucléico
|
AU6475901A
(en)
|
2000-05-22 |
2001-12-03 |
Merck And Company Inc |
System and method for assessing the performance of a pharmaceutical agent delivery system
|
US6733485B1
(en)
|
2001-05-25 |
2004-05-11 |
Advanced Bionics Corporation |
Microstimulator-based electrochemotherapy methods and systems
|
US20040204669A1
(en)
*
|
2001-07-05 |
2004-10-14 |
Hofmann Gunter A. |
Apparatus for electroporation mediated delivery for drugs and genes
|
US7713740B2
(en)
*
|
2001-08-24 |
2010-05-11 |
University Of South Florida |
Method of using electric fields to facilitate the entry of molecules into cells in vivo
|
CN101988071B
(zh)
|
2001-10-11 |
2016-07-06 |
默沙东公司 |
丙型肝炎病毒疫苗
|
ATE467680T1
(de)
|
2001-10-11 |
2010-05-15 |
Merck Sharp & Dohme |
Hepatitis-c-virus-impfstoff
|
BR0214018A
(pt)
*
|
2001-11-08 |
2005-04-19 |
Univ California |
Métodos e composições para a correção de distúrbios de condução cardìaca
|
JP2005513062A
(ja)
*
|
2001-12-14 |
2005-05-12 |
ジェネトロニクス インコーポレイテッド |
パルス電場を使用した粒子支援ポリヌクレオチド免疫方法
|
IL162844A0
(en)
*
|
2002-01-18 |
2005-11-20 |
Inovio As |
Use of an expression vector for preparing pharmaceutical compositions
|
US8209006B2
(en)
|
2002-03-07 |
2012-06-26 |
Vgx Pharmaceuticals, Inc. |
Constant current electroporation device and methods of use
|
JP2005518904A
(ja)
|
2002-03-07 |
2005-06-30 |
マーク アンド カンパニー インコーポレイテッド |
電気的刺激の側面を備えた臨床用注射器
|
US7245963B2
(en)
*
|
2002-03-07 |
2007-07-17 |
Advisys, Inc. |
Electrode assembly for constant-current electroporation and use
|
US6912417B1
(en)
*
|
2002-04-05 |
2005-06-28 |
Ichor Medical Systmes, Inc. |
Method and apparatus for delivery of therapeutic agents
|
CN100455328C
(zh)
|
2002-04-16 |
2009-01-28 |
塞托·帕尔斯科技公司 |
借助于平移电场和电极极性反转治疗生物体部位的设备
|
US20040106896A1
(en)
*
|
2002-11-29 |
2004-06-03 |
The Regents Of The University Of California |
System and method for forming a non-ablative cardiac conduction block
|
US7328064B2
(en)
|
2002-07-04 |
2008-02-05 |
Inovio As |
Electroporation device and injection apparatus
|
US9364664B2
(en)
|
2004-03-08 |
2016-06-14 |
Ichor Medical Systems, Inc. |
Apparatus for electrically mediated delivery of therapeutic agents
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
EP1865969A4
(fr)
*
|
2005-03-19 |
2009-07-15 |
Univ California |
Administration ex vivo, dans des cellules, de genes, de proteines et de medicaments mediee par un reseau de champ electrique de force ultrafaible (lsefn)
|
ES2948791T3
(es)
|
2005-06-17 |
2023-09-19 |
Msd Italia Srl |
Vacuna de ácido nucleico contra el virus de la hepatitis C
|
AU2007215328A1
(en)
*
|
2006-02-13 |
2007-08-23 |
Oncolytics Biotech Inc. |
Use of local immune suppression to enhance oncolytic viral therapy
|
US20100285040A1
(en)
|
2006-11-17 |
2010-11-11 |
Iacob Mathiesen |
Methods of enhancing immune response using electroporation-assisted vaccination and boosting
|
CA2703263C
(fr)
|
2007-11-01 |
2014-03-18 |
Perseid Therapeutics Llc |
Polypeptide immunosuppresseur et acides nucleiques
|
ES2588738T3
(es)
*
|
2008-04-04 |
2016-11-04 |
The Trustees Of The University Of Pennsylvania |
Secuencias de consenso de proteínas del virus Chikungunya, moléculas de ácido nucleico que las codifican, y composiciones y métodos de uso de las mismas
|
WO2009124309A2
(fr)
|
2008-04-04 |
2009-10-08 |
The Trustees Of The University Of Pennsylvania |
Vaccins et produits immunothérapeutiques utilisant de l’il-28 et compositions et procédés pour leur utilisation
|
EP2147697A1
(fr)
|
2008-07-21 |
2010-01-27 |
Centre National De La Recherche Scientifique-CNRS |
Procédé et dispositif pour appliquer des champs électriques dans un matériau conducteur
|
EP2156860A1
(fr)
|
2008-08-20 |
2010-02-24 |
Centre National De La Recherche Scientifique-CNRS |
Procédé de fabrication d'électrodes isolées pour l'application de champs électriques dans un matériau conducteur
|
US8207138B2
(en)
|
2009-05-19 |
2012-06-26 |
Medtronic, Inc. |
Methods and devices for improved efficiency of RNA delivery to cells
|
US20100298697A1
(en)
*
|
2009-05-19 |
2010-11-25 |
Medtronic, Inc. |
Method and devices for improved efficiency of rna delivery to cells
|
KR20120093163A
(ko)
|
2009-09-14 |
2012-08-22 |
더 트러스티스 오브 더 유니버시티 오브 펜실바니아 |
Il-15 수용체 알파 및/또는 이를 인코딩하는 핵산 분자를 포함하는 백신 및 면역 치료제, 및 이를 이용하는 방법
|
BR112012010357B1
(pt)
|
2009-11-02 |
2022-05-24 |
Inovio Pharmaceuticals, Inc. |
Proteínas de consenso de vírus de doença de febre aftosa (fmdv), sequências de codificação para as mesmas e vacinas feitas a partir das mesmas
|
US8298820B2
(en)
|
2010-01-26 |
2012-10-30 |
The Trustees Of The University Of Pennsylvania |
Influenza nucleic acid molecules and vaccines made therefrom
|
AU2011213559B2
(en)
|
2010-02-08 |
2015-05-07 |
The Trustees Of The University Of Pennsylvania |
Nucleic acid molecules encoding RANTES, and compositions comprising and methods of using the same
|
BR112013007051A2
(pt)
|
2010-09-27 |
2019-07-02 |
Inovio Pharmaceuticals Inc [Us/Is] |
construções de antígenio de consenso e vacinas feitas dos mesmos e métodos de uso das mesmas para tratar a malária
|
EP3909973A3
(fr)
|
2010-11-12 |
2022-01-26 |
The Trustees Of The University Of Pennsylvania |
Antigènes de la prostate de consensus, molécules d'acide nucléique les codant et leur utilisations
|
EP2670443A4
(fr)
|
2011-01-31 |
2015-10-14 |
Univ Pennsylvania |
Molécules d'acide nucléique codant de nouveaux antigènes d'herpès, vaccin les comprenant et procédés pour les utiliser
|
US9238679B2
(en)
|
2011-02-11 |
2016-01-19 |
The Trustees Of The University Of Pennslyvania |
Nucleic acid molecule encoding hepatitis B virus core protein and surface antigen protein and vaccine comprising the same
|
EA032364B1
(ru)
|
2011-02-11 |
2019-05-31 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Молекула нуклеиновой кислоты, кодирующая коровый белок вируса гепатита в, и вакцина, содержащая указанную молекулу
|
KR20140068000A
(ko)
|
2011-06-15 |
2014-06-05 |
크론테크 파마 아베 |
주사 바늘 및 장치
|
WO2013055418A2
(fr)
|
2011-07-11 |
2013-04-18 |
Inovio Pharmaceuticals, Inc. |
Vaccins fournissant une protection croisée contre les arénavirus et leur procédé d'utilisation
|
CN104245719B
(zh)
|
2011-12-12 |
2016-09-14 |
宾夕法尼亚大学托管会 |
包含改进的il-12基因构建体的组合物和疫苗、免疫治疗剂及其使用方法
|
US9750795B2
(en)
|
2011-12-12 |
2017-09-05 |
The Trustees Of The University Of Pennsylvania |
Proteins comprising MRSA PBP2a and fragments thereof, nucleic acids encoding the same, and compositions and their use to prevent and treat MRSA infections
|
EP2836505B1
(fr)
|
2012-04-10 |
2019-01-23 |
The Trustees Of The University Of Pennsylvania |
Antigènes consensus du virus syncytial respiratoire humain, constructions d'acide nucléique et vaccins préparés à partir de celles-ci, et leurs procédés d'utilisation
|
KR102351881B1
(ko)
|
2012-04-12 |
2022-01-18 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
필로바이러스 공통 항원, 이로부터 제조된 핵산 구조체 및 백신, 및 이를 사용하는 방법
|
DE102012013534B3
(de)
|
2012-07-05 |
2013-09-19 |
Tobias Sokolowski |
Vorrichtung für repetitive Nervenstimulation zum Abbau von Fettgewebe mittels induktiver Magnetfelder
|
WO2014064534A2
(fr)
|
2012-10-05 |
2014-05-01 |
Chrontech Pharma Ab |
Aiguille d'injection, dispositif, compositions immunogènes et procédé d'utilisation
|
PL2931304T3
(pl)
|
2012-12-13 |
2021-11-08 |
The Trustees Of The University Of Pennsylvania |
Szczepionka wt1
|
EA201992251A1
(ru)
|
2013-03-15 |
2020-05-08 |
Дзе Трастиз Оф Дзе Юниверсити Оф Пенсильвания |
Противораковые вакцины и способы лечения с их применением
|
KR20230062666A
(ko)
|
2013-03-15 |
2023-05-09 |
더 트러스티스 오브 더 유니버시티 오브 펜실베니아 |
구제역 바이러스 (fmdv) 공통 단백질, 그에 대한 코딩 서열 및 그로부터 제조된 백신
|
US10272144B2
(en)
|
2013-07-31 |
2019-04-30 |
Bioventures, Llc |
Compositions for and methods of treating and preventing targeting tumor associated carbohydrate antigens
|
EP3080159A4
(fr)
|
2013-12-13 |
2017-08-02 |
The Trustees Of The University Of Pennsylvania |
Constructions d'anticorps d'adn et procédé d'utilisation
|
WO2016089862A1
(fr)
|
2014-12-01 |
2016-06-09 |
The Trustees Of The University Of Pennsylvania |
Constructions d'anticorps d'adn et leur procédé d'utilisation
|
US11491342B2
(en)
|
2015-07-01 |
2022-11-08 |
Btl Medical Solutions A.S. |
Magnetic stimulation methods and devices for therapeutic treatments
|
US20180001107A1
(en)
|
2016-07-01 |
2018-01-04 |
Btl Holdings Limited |
Aesthetic method of biological structure treatment by magnetic field
|
US11266850B2
(en)
|
2015-07-01 |
2022-03-08 |
Btl Healthcare Technologies A.S. |
High power time varying magnetic field therapy
|
US10695575B1
(en)
|
2016-05-10 |
2020-06-30 |
Btl Medical Technologies S.R.O. |
Aesthetic method of biological structure treatment by magnetic field
|
WO2017055522A1
(fr)
|
2015-09-29 |
2017-04-06 |
Academisch Medisch Centrum |
Protéines env stabilisées du vih
|
US11253717B2
(en)
|
2015-10-29 |
2022-02-22 |
Btl Healthcare Technologies A.S. |
Aesthetic method of biological structure treatment by magnetic field
|
WO2017136758A1
(fr)
|
2016-02-05 |
2017-08-10 |
Inovio Pharmaceuticals, Inc. |
Vaccins anticancéreux et méthodes de traitement les utilisant
|
SG11201808236YA
(en)
|
2016-03-28 |
2018-10-30 |
Ichor Medical Systems Inc |
Method and apparatus for delivery of therapeutic agents
|
CA3020426A1
(fr)
|
2016-04-13 |
2017-10-19 |
Synthetic Genomics, Inc. |
Systemes de replicon d'arterivirus recombinant et utilisations correspondantes
|
US11247039B2
(en)
|
2016-05-03 |
2022-02-15 |
Btl Healthcare Technologies A.S. |
Device including RF source of energy and vacuum system
|
US11464993B2
(en)
|
2016-05-03 |
2022-10-11 |
Btl Healthcare Technologies A.S. |
Device including RF source of energy and vacuum system
|
US11534619B2
(en)
|
2016-05-10 |
2022-12-27 |
Btl Medical Solutions A.S. |
Aesthetic method of biological structure treatment by magnetic field
|
US10583287B2
(en)
|
2016-05-23 |
2020-03-10 |
Btl Medical Technologies S.R.O. |
Systems and methods for tissue treatment
|
US10556122B1
(en)
|
2016-07-01 |
2020-02-11 |
Btl Medical Technologies S.R.O. |
Aesthetic method of biological structure treatment by magnetic field
|
WO2018075235A1
(fr)
|
2016-10-17 |
2018-04-26 |
Synthetic Genomics, Inc. |
Systèmes réplicons de virus recombinants et leurs utilisations
|
AU2017372731B2
(en)
|
2016-12-05 |
2024-05-23 |
Janssen Pharmaceuticals, Inc. |
Compositions and methods for enhancing gene expression
|
WO2019042950A1
(fr)
|
2017-08-26 |
2019-03-07 |
Academisch Medisch Centrum |
Immunogènes glycoprotéiques d'enveloppe de vih améliorés
|
JP7352547B2
(ja)
|
2017-12-13 |
2023-09-28 |
イノビオ ファーマシューティカルズ,インコーポレイティド |
メソセリンを標的とするがんワクチンおよびその使用
|
KR102560562B1
(ko)
|
2017-12-13 |
2023-07-31 |
이노비오 파마수티컬즈, 인크. |
Muc16을 표적화하는 암 백신 및 이의 용도
|
WO2019118763A1
(fr)
|
2017-12-13 |
2019-06-20 |
Inovio Pharmaceuticals Inc. |
Vaccins anticancéreux ciblant l'antigène exprimé de façon préférentielle dans le mélanome (prame) et ses utilisations
|
EA202091513A1
(ru)
|
2017-12-19 |
2020-09-09 |
Янссен Сайенсиз Айрлэнд Анлимитед Компани |
Вакцины против вируса гепатита b (hbv) и их применение
|
US11389531B2
(en)
|
2017-12-19 |
2022-07-19 |
Janssen Sciences Ireland Unlimited Company |
Methods and apparatus for the delivery of hepatitis B virus (HBV) vaccines
|
MA51311A
(fr)
|
2017-12-19 |
2020-10-28 |
Janssen Sciences Ireland Unlimited Co |
Vaccins contre le virus de l'hépatite b (vhb) et utilisations associées
|
US11020476B2
(en)
|
2017-12-19 |
2021-06-01 |
Janssen Sciences Ireland Unlimited Company |
Methods and compositions for inducing an immune response against Hepatitis B Virus (HBV)
|
MA51312A
(fr)
|
2017-12-19 |
2020-10-28 |
Bavarian Nordic As |
Méthodes et compositions permettant d'induire une réponse immunitaire contre le virus de l'hépatite b (vhb)
|
MX2020007675A
(es)
|
2018-01-19 |
2020-09-14 |
Janssen Pharmaceuticals Inc |
Induccion y mejora de respuestas inmunes utilizando sistemas de replicon recombinante.
|
DE202020005828U1
(de)
|
2019-04-11 |
2022-09-06 |
BTL Medical Solutions as. |
Vorrichtungen zur Schönheitsbehandlung biologischer Strukturen durch Hochfrequenz- und Magnetenergie
|
US20220305115A1
(en)
|
2019-06-18 |
2022-09-29 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives
|
WO2020255016A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de dihydropyrimidine en tant que modulateurs de l'assemblage des capsides
|
WO2020254876A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Administration de particules de type viral de vaccins contre le virus de l'hépatite b (vhb)
|
CA3141238A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Vaccins contre le virus de l'hepatite b (vhb) et utilisations associees
|
CA3140702A1
(fr)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Combinaison de vaccins contre le virus de l'hepatite b (vhb) et de derives de dihydropyrimidine en tant que modulateurs d'assemblage de capside
|
WO2020255019A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'un dérivé de la quinazoline
|
WO2020255039A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Association de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de quinazoline
|
CN114340663A
(zh)
|
2019-06-18 |
2022-04-12 |
爱尔兰詹森科学公司 |
乙型肝炎病毒(HBV)疫苗和靶向HBV的RNAi的组合
|
EP3986915A1
(fr)
|
2019-06-18 |
2022-04-27 |
Janssen Sciences Ireland Unlimited Company |
Construction de l'interleukine 12 recombinante et ses utilisations
|
CA3143634A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combinaison de vaccins contre le virus de l'hepatite b (vhb) et d'anticorps anti-pd-1
|
CA3141003A1
(fr)
|
2019-06-18 |
2020-12-24 |
Helen Horton |
Association de vaccins contre le virus de l'hepatite b (vhb) et d'inhibiteurs de pd-l1
|
WO2020255012A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combinaison de vaccins contre le virus de l'hépatite b (hbv) et de modulateurs d'assemblage de capsides qui sont des dérivés de sulfonamide
|
WO2020255042A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'un dérivé de pyrimidine
|
WO2020255007A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'arni ciblant le virus de l'hépatite b
|
JP2022536850A
(ja)
|
2019-06-18 |
2022-08-19 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
B型肝炎ウイルス(hbv)ワクチンおよび抗pd-1または抗pd-l1抗体の組合せ
|
WO2020255021A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et d'inhibiteur de pdl1 ou pd1 à petite molécule
|
WO2020255035A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de dérivés de pyrimidine
|
WO2020255022A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de dérivés d'aminopyridine en tant qu'inhibiteurs de hpk1
|
WO2020255010A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combinaison d'une construction d'interleukine 12 recombinante et de vaccins contre le virus de l'hépatite b (vhb)
|
US20220249647A1
(en)
|
2019-06-18 |
2022-08-11 |
Janssen Sciences Ireland Unlimited Company |
Combination of hepatitis b virus (hbv) vaccines and dihydropyrimidine derivatives as capsid assembly modulators
|
WO2020255013A1
(fr)
|
2019-06-18 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Combinaison de vaccins contre le virus de l'hépatite b (vhb) et de modulateurs d'assemblage de capside qui sont des dérivés d'amide
|
WO2020255063A1
(fr)
|
2019-06-20 |
2020-12-24 |
Janssen Sciences Ireland Unlimited Company |
Administration par nanoporteurs glucidiques, de vaccins contre le virus de l'hépatite b (vhb)
|
AU2020295807A1
(en)
|
2019-06-20 |
2022-02-17 |
Janssen Sciences Ireland Unlimited Company |
Lipid nanoparticle or liposome delivery of hepatitis B virus (HBV) vaccines
|
US11878167B2
(en)
|
2020-05-04 |
2024-01-23 |
Btl Healthcare Technologies A.S. |
Device and method for unattended treatment of a patient
|
CA3173876A1
(fr)
|
2020-05-04 |
2021-11-11 |
Tomas SCHWARZ |
Dispositif et methode pour traitement automatise d'un patient
|
CN116133668A
(zh)
|
2020-06-12 |
2023-05-16 |
罗切斯特大学 |
ACE-tRNA的编码和表达
|
JP2023533528A
(ja)
|
2020-07-08 |
2023-08-03 |
ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー |
Hbvに対するrnaレプリコンワクチン
|
WO2022133230A1
(fr)
|
2020-12-18 |
2022-06-23 |
Janssen Pharmaceuticals, Inc. |
Polythérapie pour le traitement d'une infection par le virus de l'hépatite b
|
JP2024501022A
(ja)
|
2020-12-28 |
2024-01-10 |
アークトゥルス セラピューティクス, インコーポレイテッド |
Hbvを標的とする転写活性化因子様エフェクターヌクレアーゼ(talen)
|
US11896816B2
(en)
|
2021-11-03 |
2024-02-13 |
Btl Healthcare Technologies A.S. |
Device and method for unattended treatment of a patient
|
WO2023150753A1
(fr)
|
2022-02-07 |
2023-08-10 |
University Of Rochester |
Séquences optimisées pour une expression d'adn améliorée et/ou une suppression de mutation non sens
|
WO2023233290A1
(fr)
|
2022-05-31 |
2023-12-07 |
Janssen Sciences Ireland Unlimited Company |
Agents d'arni ciblant pd-l1
|